We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+12.21%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$53.1B
AUM Growth
+$4.7B
(+9.7%)
Cap. Flow
-$415M
Cap. Flow
% of AUM
-0.78%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
2,495
New
186
Increased
937
Reduced
1,188
Closed
172
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$144M |
| 2 |
NVIDIA
NVDA
|
+$137M |
| 3 |
GE Aerospace
GE
|
+$129M |
| 4 |
Dell
DELL
|
+$91.3M |
| 5 |
Comcast
CMCSA
|
+$88.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$103M |
| 2 |
Microchip Technology
MCHP
|
+$98.3M |
| 3 |
Steel Dynamics
STLD
|
+$87M |
| 4 |
UnitedHealth
UNH
|
+$79.5M |
| 5 |
Walmart Inc
WMT
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.58% |
| 2 | Consumer Discretionary | 13.58% |
| 3 | Healthcare | 12.97% |
| 4 | Financials | 12.15% |
| 5 | Industrials | 12.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DAWN
2251
DELISTED
Day One Biopharmaceuticals
DAWN
| $148K | ﹤0.01% |
+10,158
| New | +$123K |
|
2252
PDS Biotechnology
PDSB
$40.9M
| $145K | ﹤0.01% |
29,265
+6,838
| +30% | +$34K |
|
2253
Kinross Gold
KGC
$32.5B
| $142K | ﹤0.01% |
23,513
-3,981
| -14% | -$21.8K |
|
2254
MannKind Corp
MNKD
$1.26B
| $139K | ﹤0.01% |
38,166
-1,132
| -3% | -$4.32K |
|
2255
GrowGeneration
GRWG
$85.9M
| $139K | ﹤0.01% |
+55,293
| New | +$135K |
|
2256
X4 Pharmaceuticals
XFOR
$421M
| $138K | ﹤0.01% |
5,478
+3,435
| +168% | +$83.5K |
|
2257
MaxCyte
MXCT
$130M
| $138K | ﹤0.01% |
29,314
+13,450
| +85% | +$52.4K |
|
|
CEPU
2258
Central Puerto
CEPU
$2.07B
| $137K | ﹤0.01% |
15,104
-101,087
| -87% | -$727K |
|
2259
Alta Equipment Group
ALTG
$237M
| $137K | ﹤0.01% |
11,078
-28,081
| -72% | -$303K |
|
2260
Tredegar Corp
TG
$292M
| $134K | ﹤0.01% |
24,790
-167,448
| -87% | -$826K |
|
2261
CorMedix
CRMD
$591M
| $133K | ﹤0.01% |
35,354
+19,769
| +127% | +$68K |
|
2262
Newmark Group
NMRK
$2.52B
| $132K | ﹤0.01% |
12,044
-6,864
| -36% | -$51.8K |
|
2263
Gogo Inc
GOGO
$432M
| $131K | ﹤0.01% |
12,961
-1,952
| -13% | -$20.7K |
|
2264
Oric Pharmaceuticals
ORIC
$1.41B
| $130K | ﹤0.01% |
14,146
+2,947
| +26% | +$21.3K |
|
2265
Relay Therapeutics
RLAY
$4.37B
| $127K | ﹤0.01% |
+11,501
| New | +$97K |
|
2266
The Honest Company
HNST
$561M
| $127K | ﹤0.01% |
38,340
-175,694
| -82% | -$320K |
|
2267
Arhaus
ARHS
$1.34B
| $125K | ﹤0.01% |
+10,577
| New | +$99.6K |
|
2268
Humacyte
HUMA
$201M
| $123K | ﹤0.01% |
+43,337
| New | +$111K |
|
|
SPWR
2269
DELISTED
SunPower Corporation Common Stock
SPWR
| $122K | ﹤0.01% |
25,169
-163,292
| -87% | -$779K |
|
2270
Sunstone Hotel Investors
SHO
$2.01B
| $119K | ﹤0.01% |
11,096
-9,963
| -47% | -$98.2K |
|
2271
Enviri
NVRI
$615M
| $118K | ﹤0.01% |
13,118
+2,180
| +20% | +$14.9K |
|
2272
TeraWulf
WULF
$8.08B
| $115K | ﹤0.01% |
47,943
+18,833
| +65% | +$25.7K |
|
2273
Custom Truck One Source
CTOS
$2.42B
| $114K | ﹤0.01% |
18,457
+6,535
| +55% | +$38.5K |
|
2274
Stem
STEM
$50.9M
| $114K | ﹤0.01% |
1,470
-32
| -2% | -$2.21K |
|
|
SLGC
2275
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $110K | ﹤0.01% |
43,373
+8,017
| +23% | +$18.7K |
|
Similar funds
VGA
AQR Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, AQR Capital Management held 2,495 positions worth $53.1B, up 9.7% from $48.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
AQR Capital Management's Q4 2023 filing shows 186 new, 937 increased, 1,188 reduced and 172 closed positions. Its largest new stake was NCR Atleos: 518,383 shares worth $12.5M. The largest sale was Pfizer, an estimated $103M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 23% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- AQR Capital Management's largest Q4 2023 buy was NCR Atleos: 518,383 shares worth $12.5M.
- AQR Capital Management added most to Amazon in Q4 2023, an estimated $144M increase.
- AQR Capital Management's biggest Q4 2023 reduction was Pfizer, cutting an estimated $103M.
- AQR Capital Management fully exited Activision Blizzard in Q4 2023, selling an estimated $38.5M.
- AQR Capital Management's ten largest holdings make up 15% of its $53.1B portfolio in Q4 2023.
- AQR Capital Management opened 186 new positions and closed 172 in Q4 2023.
- AQR Capital Management's portfolio value rose 9.7% quarter-over-quarter to $53.1B.
Based on AQR Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.